tradingkey.logo

BRIEF-Organovo’S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company

ReutersFeb 25, 2025 2:38 PM

Feb 25 (Reuters) - Eli Lilly and Co LLY.N:

  • ORGANOVO’S FXR PROGRAM, INCLUDING FXR314, TO BE ACQUIRED BY ELI LILLY AND COMPANY
  • ORGANOVO HOLDINGS INC - TO RECEIVE UPFRONT PAYMENT AND MILESTONES FOR FXR314
  • ORGANOVO HOLDINGS INC - LILLY ACQUIRES ALL COMMERCIAL AND IP RIGHTS TO FXR PROGRAM

Source text: ID:nGNX2v9LqC

Further company coverage: LLY.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.